Atea Pharmaceuticals press release
Atea Pharmaceuticals, Inc. announced the initiation of a first-in-human Phase 1 clinical trial evaluating AT-587, for the treatment of hepatitis E virus (HEV) infection.
AT-587 is a proprietary oral antiviral nucleotide analog being developed for the treatment of HEV, a potentially serious liver disease that can lead to chronic infection, cirrhosis and liver failure in certain patient populations.
The Phase 1 trial is a randomized, double-blind, placebo-controlled, sequential dose-escalation study designed to evaluate the safety, tolerability and pharmacokinetics of AT-587 in healthy volunteers. The study includes both single ascending dose and multiple ascending dose components, as well as an embedded food-effect assessment.
Read the full press release here.
Source : Atea Pharmaceuticals, Inc.
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.